CLASS ACTION UPDATE for ADMS, REAL and MMSI: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

NEW YORK, NY / ACCESSWIRE / December 13, 2019 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

ADMS Shareholders Click Here: https://www.zlk.com/pslra-1/adamas-pharmaceuticals-inc-loss-form?prid=4878&wire=1
REAL Shareholders Click Here: https://www.zlk.com/pslra-1/the-realreal-inc-loss-form?prid=4878&wire=1
MMSI Shareholders Click Here: https://www.zlk.com/pslra-1/merit-medical-systems-inc-loss-form?prid=4878&wire=1

* ADDITIONAL INFORMATION BELOW *

Adamas Pharmaceuticals, Inc. (NASDAQGM:ADMS)

ADMS Lawsuit on behalf of: investors who purchased August 8, 2017 - September 30, 2019
Lead Plaintiff Deadline : February 10, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/adamas-pharmaceuticals-inc-loss-form?prid=4878&wire=1

According to the filed complaint, during the class period, Adamas Pharmaceuticals, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) health insurers were excluding Adamas's primary product, GOCOVRI, from their prescription formularies or requiring patients to use "step therapy" - i.e., making patients try immediate-release amantadine prior to covering GOCOVRI; (2) the rapid increase in physicians prescribing GOCOVRI during the Class Period was not due to its efficacy; and (3) as a result of the foregoing, the Company's financial statements about Adamas's business, operations, and prospects were materially false and misleading at all relevant times.

The RealReal, Inc. (NASDAQ:REAL)

REAL Lawsuit on behalf of: investors who purchased all persons and entities who purchased RealReal common stock pursuant and/or traceable to the Company's registration statement issued in connection with the Company's June 27, 2019 initial public offering.
Lead Plaintiff Deadline : January 24, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/the-realreal-inc-loss-form?prid=4878&wire=1

According to the filed complaint, (1) the Company's employees received little training on how to spot fake items; (2) the Company's strict quotas on its employees exacerbated product authentication issues; (3) consequently, the potential for counterfeit or mislabeled items to make it through Company's authentication process was higher than disclosed; and (4) as a result, Defendants' statements about the Company's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Merit Medical Systems, Inc. (NASDAQ:MMSI)

MMSI Lawsuit on behalf of: investors who purchased February 26, 2019 - October 30, 2019
Lead Plaintiff Deadline : February 3, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/merit-medical-systems-inc-loss-form?prid=4878&wire=1

According to the filed complaint, during the class period, Merit Medical Systems, Inc. made materially false and/or misleading statements and/or failed to disclose that: (a) the integrations of acquired companies Cianna Medical, Inc. and Vascular Insights, LLC, including their products, sales people, and R&D facilities, had caused operational disruptions and reduced sales and were months behind schedule; (b) sales of acquired company products had slowed substantially due to pre-acquisition pipeline fill, in particular for Vascular Insights products which, as late as July 2019, had zero orders during FY19; and (c) in light of the foregoing, the Company's reported financial guidance for FY19 and FY20 was made without a reasonable basis.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP